GBI Research

GBI Research is a business intelligence firm based in London, United Kingdom with additional offices in the United States and India.
The firm focuses its research on pharmaceuticals, medical devices, alternative energy, power, clean technology, oil and gas, and chemicals sectors. It publishes strategic intelligence reports based on primary and secondary research, proprietary databases, and analysis. The firm offers insights and analysis at the company, country, and industry level including competitor and market data, valuations, clinical and market trends, product pipelines and forecasts.

GBI Research leverage extensive proprietary databases and employs novel data interrogation methodologies to generate new and meaningful analyses and insights.

Their data and coverage are informed by close collaboration with a global network of domain-specific external partners; which allows to deliver novel, thought-provoking and idea-generating insights that clients would normally struggle to access.

With in house team of researchers and analysts located across the UK, US and Asia Pacific they provides expert and insightful commentary to support evidence-based analyses of established and emerging markets.

GBI Research has developed an innovative portfolio of products and research solutions to fulfill the varied needs of a diverse client base and more than 2,000 clients benefit from the GBI Research product set.

Latest Articles & Reports by GBI Research

Global Dermatology Drugs Growth Driven by

“Global Dermatology Drugs Market to 2023” – Growth Driven by Increased Uptake of Interleukin Receptor Inhibitors for Psoriasis and Atopic Dermatitis. Since 2014, five potential blockbuster drugs have been approved […]

Cancer vaccines market will soar to $7.5 billion by 2022

Global revenues for the cancer vaccines market are forecast to grow at a compound annual growth rate of 16.93%, from $2.5 billion in 2015 to $7.5 billion in 2022. Cancer […]

Global Viral Infections Market to 2021 – Promising New Competitors and Expanding Treatment Population to Offset Increased Uptake of Generics

Global Viral Infections Market to 2021 – Promising New Competitors and Expanding Treatment Population to Offset Increased Uptake of Generics Summary Viruses are infectious particles comprising a nucleic acid core […]

Global Non-Hematological Cancers Market to 2021 – Strong growth driven by increased uptake of low toxicity targeted treatments and versatile biologics

Global Non-Hematological Cancers Market to 2021 – Strong growth driven by increased uptake of low toxicity targeted treatments and versatile biologics Summary In 2012, there were 32.6 million people living […]

Frontier Pharma: Schizophrenia and Associated Indications – Small but Diverse Range of First-in-Class Molecular Targets Hold Promise for Treatment of Negative and Cognitive Symptoms

Frontier Pharma: Schizophrenia and Associated Indications – Small but Diverse Range of First-in-Class Molecular Targets Hold Promise for Treatment of Negative and Cognitive Symptoms Summary Schizophrenia is a severe mental […]

Alzheimer’s Therapeutics in Asia-Pacific Markets to 2021 – Growth Driven by Rising Prevalence, Growing Awareness and Expected Launch of Disease Modifying Therapies

Alzheimer’s Disease Market in Asia-Pacific to Surpass $5 Billion by 2021, says GBI Research

The Asia-Pacific (APAC) Alzheimer’s disease market will grow from $3 billion in 2014 to $5.1 billion in 2021, representing a robust Compound Annual Growth Rate of 7.9%, according to business intelligence provider GBI Research.

Latest report* states that the main driver of this impressive growth, which will occur across the APAC countries of India, China, Australia and Japan, will be rising and aging populations, as Alzheimer’s disease is significantly more prevalent among the elderly.

Asthma Therapeutics in Asia-Pacific Markets to 2021 – High Prevalence and Launch of Late-Stage Biologics will Drive the Market in Spite of Affordability Concerns

Asthma Therapeutics in Asia-Pacific Markets to 2021 – High Prevalence and Launch of Late-Stage Biologics will Drive the Market in Spite of Affordability Concerns Summary Asthma is a common chronic […]

Frontier Pharma: Breast Cancer – First-in-Class Innovation Clustered Around Growth Factor Signalling Processes

Breast Cancer is Only Pharmaceutical Pipeline with over 1000 Drugs in Development, says GBI Research

The breast cancer treatment pipeline’s exceptional levels of activity and innovation, with a staggering 1,050 drugs in active development across all stages and 347 first-in-class programs, may significantly alter the clinical and commercial landscape of the disease market over the next decade, according to business intelligence provider GBI Research.

Parkinson’s Disease Therapeutics in Major Developed Markets to 2021: Early Pipeline Shifts Towards Disease-Modifying Therapies, while Short Term Growth Driven by Long-Acting Symptomatic Treatments

Parkinson’s Disease Therapeutics in Major Developed Markets to 2021: Early Pipeline Shifts Towards Disease-Modifying Therapies, while Short Term Growth Driven by Long-Acting Symptomatic Treatments Summary Parkinson’s Disease (PD) is a […]

Breast Cancer Therapeutics in Asia-Pacific Markets to 2021 – Growth Driven by Increasing Uptake of Premium Priced Biologics and Rising Prevalence

APAC Breast Cancer Market Will Rise Substantially to $3.4 Billion by 2021, says GBI Research

The Asia-Pacific (APAC) breast cancer market is set to experience considerable expansion from $1.9 billion in 2014 to $3.4 billion by 2021, at a robust Compound Annual Growth Rate (CAGR) of 8.5%, according to business intelligence provider GBI Research.
Such growth, which will occur across the APAC regions of India, China, Australia, and Japan, will be driven by aging populations, changing lifestyle habits, improved survival rates, and a number of new approvals for drugs that are expected to supplement current market leaders.

Alzheimer’s Disease Therapeutics in Major Developed Markets to 2021 – Aging Population and Improved Disease Understanding Increase Demand for Disease Modifying Agents

Alzheimer’s Disease Market Will More Than Double to $10.4 Billion by 2021, says GBI Research

The Alzheimer’s disease market will more than double from just under $5 billion in 2014 to an estimated $10.4 billion in 2021, at a Compound Annual Growth Rate (CAGR) of 11%, according to business intelligence provider GBI Research.

Mushtaq comments: “The fact that people are living longer across the globe means more cases of the disease are developing, and this has posed a growing public health crisis, which represents a very serious disease burden for patients and carers alike.

Frontier Pharma: Parkinson’s Disease – Identifying and Commercializing First-in-Class Innovation

Parkinson’s Disease Treatment Pipeline Holds Significant Potential for Patients and Investors, says GBI Research

The Parkinson’s disease treatment pipeline presents a distinctly more promising landscape than the current market, which is burdened with unmet needs and a lack of disease-modifying drugs, says business intelligence provider GBI Research.

According to the company’s latest report*, the current Parkinson’s disease treatment market relies on neuromodulators, and although levodopa and dopaminergic treatments can be used to relieve symptoms, there is not an agent that has demonstrated neuroprotective properties to prevent or at least significantly slow neuronal cell death.

Type 2 Diabetes Mellitus Therapeutics in Asia-Pacific Markets to 2021 – Increasing Usage of Newer Therapies and Expanding Treatment Population to Encourage Robust Growth

Asia-Pacific Type 2 Diabetes Mellitus Treatment Market Will Exceed $10 Billion by 2021, says GBI Research

The treatment market for Type 2 Diabetes Mellitus (T2DM) in the Asia-Pacific (APAC) region will increase from a little under $6.1 billion in 2014 to just over $10 billion by 2021, at a Compound Annual Growth Rate (CAGR) of 7.7%, according to business intelligence provider GBI Research.

Substantial growth, which will occur across the countries of China, India, Japan and Australia, will be driven by the rapidly expanding prevalence population resulting from increasingly aging populations and sedentary lifestyles. Higher diagnosis and treatment rates, due to rising disease awareness among the public, will also play a role.

Opioids Market to 2018 – Increasing Concentration of Abuse-Resistant Branded Generics Alter Competitive Dynamics in this Flat Market

Opioids Market to 2018 – Increasing Concentration of Abuse-Resistant Branded Generics Alter Competitive Dynamics in this Flat Market Summary Leading business intelligence provider GBI Research has released its latest research […]

Risk warning: Your capital may be at risk. CFD trading is suitable for experienced traders and not beginners.